VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?

Leon Bernal-Mizrachi, MD, of Emory University, Atlanta, GA, discusses a study aiming to characterize whether NFκB2 gene rearrangement can predict response to ixazomib in multiple myeloma. This Phase II trial tests ixazomib and dexamethasone vs. ixazomib, dexamethasone and lenalidomide, randomized with NFκB2 rearrangement (NCT02765854). This interview took place at the international myeloma workshop (IMW) 2019, in Boston, MA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter